SMAD2 and neoplasm: A recent review of the above study regarding Foxp1 highlights some clinical applications to build on this knowledge of TGF-β signaling, such as engineering anti-tumor T cells without Foxp1 or small molecule disruption of Foxp1-SMAD2/3 or -DNA [157].